Ketanserin plus Psilocybin

Phase 1Small molecule

UUniversity Hospital, Basel, Switzerland

Ketanserin plus Psilocybin is one of 5 small molecule programs targeting Psilocybin. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PsilocybinRecruiting

PsilocybinPhase 1

Recruiting

Competition

Competitive Landscape

5 competitors in Psilocybin

#DrugCompanyPhaseTrials

Psilocybin

COMPASS Pathways

Phase 3

38 2

Risperdal

WWim Janssens

Phase 1

1 3

Versed

CConrado Roberto Hoffmann Filho

Phase 1

1 4

Psilocybin Therapy

UUniversity of California, San Francisco

Phase 2

1 5

Ketanserin plus Psilocybin

UUniversity Hospital, Basel, Switzerland

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Psilocybin1 trial

Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT06796361·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ketanserin plus Psilocybin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ketanserin plus Psilocybin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ketanserin plus Psilocybin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Basel, Switzerland company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity Hospital, Basel, Switzerland

Ketanserin plus Psilocybin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Psilocybin1 trial

References

Drug Info

Quick Facts

Related News